Myometrial invasion by endometrial carcinoma: evaluation with 3.0T MR imaging

Kaneda, Sachi; Fujii, Shinya; Fukunaga, Takanobu; Kakite, Suguru; Kaminou, Toshio; Kigawa, Junzo; Harada, Tasuku; Ogawa, Toshihide

doi:10.1007/s00261-011-9719-8

Cited by 16 publications

(13 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With advancements in MRI technology, diffusion-weighted imaging (DWI-MRI) applied in gynaecological diseases also has been reported in several studies with promising results [7-9]. Compared with 1.5 T, the signal-to-noise ratio at 3 T has been increased and background suppression has been improved, which allows better categorization of variable components of ovarian diseases [10,11]. Studies with focus on primary adnexal lesions evaluated by 3.0 T (3 T) still are limited to date.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of primary adnexal masses by 3T MRI: categorization with conventional MR imaging and diffusion-weighted imaging

Zhang

et al. 2012

J Ovarian Res

View full text Add to dashboard Cite

BackgroundTo investigate the 3.0-Tesla (3 T) magnetic resonance imaging (MRI) characteristics of primary adnexal lesions for discriminating benign from malignant lesions.MethodsOne hundred thirty-nine patients with pathologically proven primary adnexal masses referred for 3 T MRI assessment preoperatively were included. Baseline characteristics, components, and conventional MRI and diffusion-weighted imaging (DWI-MRI) signals were recorded and compared.ResultsThere were 22 ovarian cysts, 33 endometriomas, 43 benign tumors and 42 malignant tumors. When ovarian cyst and endometrioma were excluded, there were no significant differences in patients’ age between benign and malignant tumor (P = 0.235). There were no significant differences (P = 0.606) in the conventional MRI signals and significant difference (P = 0.008) in DWI-MRI signal between the non-malignant and malignant lesions. There was a significant difference (P = 0.000) in the apparent diffusion coefficient values (ADCs) between the non-malignant and malignant lesions.Conclusions3 T MRI categorized the characteristics of primary adnexal lesions. Conventional MRI signals were not useful for characterizing between benign and malignant lesions. DWI-MRI and ADCs were helpful for distinguishing malignant from benign ovarian lesions.

show abstract

Section: Introductionmentioning

confidence: 99%

Evaluation of primary adnexal masses by 3T MRI: categorization with conventional MR imaging and diffusion-weighted imaging

Zhang

et al. 2012

J Ovarian Res

View full text Add to dashboard Cite

show abstract

“…In patients with deep invasion of the myometrium, dynamic contrast-enhanced MRI significantly improves the signal-to-noise ratio for tumour and uterine wall muscle, allowing more accurate determination of the depth of myometrial invasion. 4,16,17 T2WI-and T 1 weighted imagingenhanced scanning have demonstrated accuracies of 73-86% and 78-88%, respectively, for assessing depth of muscle invasion, and this accuracy can be further increased to 82-92% for enhanced dynamic scanning. 9,[16][17][18] The results of the current study showed that dynamic enhanced FLASH-3D imaging technology increased the accuracy of pre-operative evaluation of depth of myometrial invasion.…”

Section: Discussionmentioning

confidence: 99%

“…4,16,17 T2WI-and T 1 weighted imagingenhanced scanning have demonstrated accuracies of 73-86% and 78-88%, respectively, for assessing depth of muscle invasion, and this accuracy can be further increased to 82-92% for enhanced dynamic scanning. 9,[16][17][18] The results of the current study showed that dynamic enhanced FLASH-3D imaging technology increased the accuracy of pre-operative evaluation of depth of myometrial invasion. The study by Emlik 4 has demonstrated that in differentiation of deep myometrial invasion from superficial myometrial invasion, the sensitivity, specificity, accuracy, PPV and NPV were 100%, 85%, 89%, 68.4%, and 100% on dynamic 3D FLASH volume interpolated gradient echo MR images.…”

Section: Discussionmentioning

confidence: 99%

“…0.05), in accord with previous reports. 4,10,13,16 The value of pre-operative staging focuses on early-stage (Stages I and II) disease. However, the accurate staging of early tumours is difficult because of the need to detect small lesions in the endometrium, given that tumours are only mildly enhanced by dynamic contrast during the early stage.…”

Section: Discussionmentioning

confidence: 99%

“…2,13,16 Enhanced MRI represents one of the most accurate methods for the pre-operative assessment of the depth of myometrial invasion. In patients with deep invasion of the myometrium, dynamic contrast-enhanced MRI significantly improves the signal-to-noise ratio for tumour and uterine wall muscle, allowing more accurate determination of the depth of myometrial invasion.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Application of FLASH-3D dynamic contrast-enhanced imaging for diagnosis of endometrial carcinoma

Xiao-hu

Qiu

et al. 2016

BJR

View full text Add to dashboard Cite

The authors Lixin Du and Xiaohu Li contributed equally to this article.Objective: To investigate the application and value of fast low-angle shot three-dimensional (FLASH-3D) dynamic contrast-enhanced MRI for the pre-operative staging of endometrial carcinoma. Methods: This prospective study enrolled 48 patients with complete clinical data and pathologically confirmed endometrial carcinoma from July 2012 to March 2014. After routine MRI examination, subjects underwent FLASH-3D dynamic contrast-enhanced examination. The dynamically enhanced features of the uterine wall and tumours were analyzed. FLASH-3D pre-operative staging and findings in relation to myometrial invasion were compared with post-operative pathological results in a double-blind manner. Results: There were 48 cases of pathologically proven endometrial carcinoma, including 34 patients with Stage I (Stage Ia 22 cases and Stage Ib 12 cases), 9 with Stage II, 3 with Stage III and 2 with Stage IV. The staging accuracy for endometrial carcinoma was 81% (39/48) using FLASH-3D dynamic contrast-enhanced sequences. The sensitivity, specificity and accuracy for the determination of deep myometrial invasion were 84%, 90% and 88%, respectively. There was no significant difference compared with the results of post-operative pathology (p . 0.05). Conclusion: FLASH-3D dynamic contrast-enhanced imaging may be valuable for the early diagnosis and preoperative staging of endometrial carcinoma. Its high accuracy for assessing deep myometrial invasion makes FLASH-3D imaging an important tool for selecting the optimal therapeutic protocol and for prognosis estimation. Advances in knowledge: FLASH-3D can significantly improve the accurate assessment of the depth of tumour invasion into the myometrium and may thus help to guide clinical surgical choices and post-operative evaluation. FLASH-3D is thus a promising technique for the routine examination of female pelvic tumours.

show abstract

Accuracy of semiquantitative dynamic contrast‐enhanced MRI for differentiating type II from type I endometrial carcinoma

Fukunaga

Fujii

Inoue

et al. 2014

Magnetic Resonance Imaging

Self Cite

View full text Add to dashboard Cite

show abstract

Myometrial invasion by endometrial carcinoma: evaluation with 3.0T MR imaging

Abstract: In evaluation of the depth of myometrial invasion by endometrial carcinoma, 3.0T MR imaging has a high diagnostic accuracy that is equivalent to that of previously reported 1.5T MR imaging.

Cited by 16 publications

References 43 publications

Evaluation of primary adnexal masses by 3T MRI: categorization with conventional MR imaging and diffusion-weighted imaging

Evaluation of primary adnexal masses by 3T MRI: categorization with conventional MR imaging and diffusion-weighted imaging

Application of FLASH-3D dynamic contrast-enhanced imaging for diagnosis of endometrial carcinoma

Accuracy of semiquantitative dynamic contrast‐enhanced MRI for differentiating type II from type I endometrial carcinoma

Contact Info

Product

Resources

About